Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and Vulvar Neoplasms

quinazolines has been researched along with Vulvar Neoplasms in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's8 (57.14)29.6817
2010's5 (35.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bourkoula, A; Livaniou, E; Papadopoulos, A; Papadopoulos, M; Paravatou-Petsotas, M; Pelecanou, M; Pietzsch, HJ; Pirmettis, I; Santos, I1
Jo, H; Kim, SH; Song, YC; Song, YS1
Fan, Z; Li, X; Liang, K; Lu, Y; Luwor, RB1
Brahimi, F; Golabi, N; Huang, Y; Jean-Claude, BJ; Larroque-Lombard, AL; Qiu, Q; Rachid, Z1
Bacha, OM; Lalancette, M; Levesque, E; Renaud, MC1
Fernandes, C; Gano, L; Kniess, T; Mendes, F; Neto, C; Oliveira, MC; Santos, I1
Borger, DR; Brard, L; Dizon, DS; Growdon, WB; Horowitz, NS; Krasner, CN; Lee, J; Liu, JF; Matulonis, UA; Olawaiye, AB1
Bavetsias, V; Gibbs, D; Jackman, AL; Jansen, G; Skelton, LA; Theti, DS; Titley, J1
Banerjee, R; Jean-Claude, BJ; McNamee, JP; Qiu, Q; Rachid, Z; Tari, AM1
Lanzi, C; Supino, R; Zanchi, C; Zuco, V; Zunino, F1
Horowitz, N; Krasner, C; Lee, LM; Olawaiye, A1
Albanell, J; Baselga, J; Bos, M; Fry, DW; Kim, YM; Mendelsohn, J1
Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF1
Hirata, A; Kometani, T; Kuwano, M; Kuwano, T; Naito, S; Ogawa, S; Ono, M1

Trials

1 trial(s) available for quinazolines and Vulvar Neoplasms

ArticleYear
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
    Gynecologic oncology, 2012, Volume: 127, Issue:1

    Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms

2012

Other Studies

13 other study(ies) available for quinazolines and Vulvar Neoplasms

ArticleYear
Synthesis and characterization of rhenium and technetium-99m tricarbonyl complexes bearing the 4-[3-bromophenyl]quinazoline moiety as a biomarker for EGFR-TK imaging.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:10

    Topics: Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Humans; Magnetic Resonance Spectroscopy; Male; Mice; Organotechnetium Compounds; Phosphorylation; Quinazolines; Rhenium; Vulvar Neoplasms

2009
Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
    Annals of the New York Academy of Sciences, 2009, Volume: 1171

    Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Female; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Tyrphostins; Vulvar Neoplasms

2009
Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.
    Cancer letters, 2011, Jul-01, Volume: 306, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Genes, ras; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Models, Biological; Phosphorylation; Quinazolines; ras Proteins; Vulvar Neoplasms

2011
A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity.
    Journal of pharmaceutical and biomedical analysis, 2011, Nov-01, Volume: 56, Issue:3

    Topics: Animals; Antinematodal Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; DNA Damage; Drug Delivery Systems; ErbB Receptors; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Nitrogen Mustard Compounds; Ovarian Neoplasms; Quinazolines; Triazenes; Vulvar Neoplasms; Xenograft Model Antitumor Assays

2011
A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor.
    European journal of gynaecological oncology, 2011, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Quinazolines; Vulvar Neoplasms

2011
Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents.
    Nuclear medicine and biology, 2012, Volume: 39, Issue:2

    Topics: Animals; Cell Line, Tumor; ErbB Receptors; Female; Fluorine Radioisotopes; Halogenation; Humans; Iodine Radioisotopes; Mice; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Radionuclide Imaging; Tissue Distribution; Vulvar Neoplasms

2012
Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
    Cancer research, 2003, Jul-01, Volume: 63, Issue:13

    Topics: Antineoplastic Agents; Biological Transport; Carcinoma, Squamous Cell; Carrier Proteins; Cell Division; Cyclopentanes; Enzyme Inhibitors; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Kinetics; Quinazolines; Receptors, Cell Surface; Recombinant Proteins; Thymidylate Synthase; Transfection; Tumor Cells, Cultured; Vulvar Neoplasms

2003
Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Alkylating Agents; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; DNA Damage; ErbB Receptors; Female; Humans; Phosphorylation; Quinazolines; Triazenes; Vulvar Neoplasms

2004
Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
    Cancer research, 2005, Mar-15, Volume: 65, Issue:6

    Topics: Adamantane; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 8; Caspases; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cinnamates; DNA Damage; Drug Synergism; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Signal Transduction; Vulvar Neoplasms

2005
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.
    Gynecologic oncology, 2007, Volume: 106, Issue:3

    Topics: Aged; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms

2007
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:11

    Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Enzyme Inhibitors; ErbB Receptors; Female; Genes, erbB-2; Humans; Male; Phosphorylation; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Recombinant Proteins; Transfection; Uterine Cervical Neoplasms; Vulvar Neoplasms

1997
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:12

    Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms

2000
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
    Cancer research, 2002, May-01, Volume: 62, Issue:9

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Movement; Cells, Cultured; Cornea; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-8; Lymphokines; Male; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Physiologic; Quinazolines; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vulvar Neoplasms

2002